Search

Your search keyword '"Muro K"' showing total 1,234 results

Search Constraints

Start Over You searched for: Author "Muro K" Remove constraint Author: "Muro K"
1,234 results on '"Muro K"'

Search Results

208. 584P - Predictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)

217. A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Gastric Cancer

219. Comparison of Surgery with Definitive Chemoradiotherapy for Potentially Resectable Esophageal Cancer: a Propensity-Score Analysis

220. Clinical Validation of a Novel Multiplex Kit for All Ras Mutations in Colorectal Cancer: Results of Rasket(Ras Key Testing) Prospective Multicenter Study

221. Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab Plus Paclitaxel vs Placebo Plus Paclitaxel Patients with Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma – Patient-Reported Outcomes and Performance Status

225. 630P - Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study

226. 592P - Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI

229. 455O - Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

230. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer

233. Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

238. Preliminary Safety Data from Randomized Phase II Study Comparing Dose-Escalated Weekly Paclitaxel Versus Standard-Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer

239. Granite-1; Phase III Trial of Everolimus (EVE) in Previously Treated Patients with Advanced Gastric Cancer (AGC): Results of Japanese Population

247. MEDICAL AND NEURO-ONCOLOGY

250. 6099 POSTER The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumour Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC)

Catalog

Books, media, physical & digital resources